Search results for "progressive"

showing 10 items of 281 documents

The Impact of Coconut Oil and Epigallocatechin Gallate on the Levels of IL-6, Anxiety and Disability in Multiple Sclerosis Patients

2020

Background: Due to the inflammatory nature of multiple sclerosis (MS), interleukin 6 (IL-6) is high in blood levels, and it also increases the levels of anxiety related to functional disability. Epigallocatechin gallate (EGCG) decreases IL-6, which could be enhanced by the anti-inflammatory effect of high ketone bodies after administering coconut oil (both of which are an anxiolytic). Therefore, the aim of this study was to assess the impact of coconut oil and EGCG on the levels of IL-6, anxiety and functional disability in patients with MS. Methods: A pilot study was conducted for four months with 51 MS patients who were randomly divided into an intervention group and a control group. The …

Male0301 basic medicineTime FactorsMediterranean dietEmotionsPilot ProjectsEpigallocatechin gallateDiet Mediterraneanmultiple sclerosisGastroenterologyCatechinBody Mass IndexDisability Evaluationchemistry.chemical_compound0302 clinical medicineProspective Studiescoconut oilNutrition and DieteticsCoconut oilfood and beveragesMiddle AgedMultiple Sclerosis Chronic ProgressiveanxietyTreatment OutcomeAnxietyFemalemedicine.symptomlcsh:Nutrition. Foods and food supplyepigallocatechin gallatemedicine.medical_specialtyfood.ingredientmedicine.drug_classlcsh:TX341-641PlaceboAnxiolyticArticle03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingfoodInternal medicinemedicineHumansExpanded Disability Status Scalebusiness.industryinterleukin-6Recovery of Function030104 developmental biologydisabilitychemistrySpainDietary SupplementsbusinessBody mass indexBiomarkers030217 neurology & neurosurgeryFood ScienceNutrients
researchProduct

Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hemat…

2004

BACKGROUND Continuous oral treatment with topotecan may be more effective than the typical 1-day and 5-day treatment schedules. In previous studies of continuous treatment with topotecan, increased intestinal side effects were reported in adult patients; however, the experience in pediatric patients and patients with high-grade glioma is quite limited. METHODS Thirty-two pediatric patients with recurrent high-grade glioma (16 females and 16 males; median age, 9.5 years) were enrolled in the current Phase I/II study. Tumor locations included the cerebral cortex (n = 5), pons (n = 18), and other sites (n = 9). An injectable formulation of topotecan was administered orally, in ice-cold orange …

MaleCancer Researchmedicine.medical_specialtyAdolescentAdministration OralAntineoplastic AgentsGastroenterologyDrug Administration Schedule03 medical and health sciences0302 clinical medicinePharmacokineticsOral administrationInternal medicineGliomaMedicineHumansDosingChild030304 developmental biologyOrange juice0303 health sciencesbusiness.industryBrain NeoplasmsGliomamedicine.disease3. Good healthSurgeryTreatment OutcomeOncology030220 oncology & carcinogenesisChild PreschoolToxicityTopotecanFemalebusinessTopotecanProgressive diseasemedicine.drugCancer
researchProduct

Postponed Is Not Canceled: Role of Craniospinal Radiation Therapy in the Management of Recurrent Infant Medulloblastoma—An Experience From the HIT-RE…

2013

Purpose To evaluate the efficacy of craniospinal irradiation (CSI) in the management of recurrent infant medulloblastoma after surgery and chemotherapy alone. Methods and Materials Seventeen pediatric medulloblastoma patients registered in the HIT-REZ 1997 and 2005 studies underwent CSI as salvage treatment at first recurrence. All patients had achieved complete remission after first-line treatment consisting of surgery and chemotherapy. Eleven patients showed metastatic disease at relapse. Five patients underwent surgery prior to radiation therapy, which resulted in complete resection in 1 case. In 1 patient, complete resection of the residual tumor was performed after CSI. Eleven patients…

MaleCancer Researchmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMedizinDisease-Free SurvivalCraniospinal IrradiationCohort Studies03 medical and health sciences0302 clinical medicineRecurrencemedicineHumansRadiology Nuclear Medicine and imagingNeoplasm MetastasisChildNeoplasm StagingProportional Hazards ModelsSalvage TherapyMedulloblastomaChemotherapyUnivariate analysisRadiationBrain Neoplasmsbusiness.industryProportional hazards modelInfantRadiotherapy Dosagemedicine.disease3. Good healthSurgeryRadiation therapyTreatment OutcomeOncologyChild Preschool030220 oncology & carcinogenesisMultivariate AnalysisFemaleCranial IrradiationNeoplasm Recurrence LocalbusinessCraniospinal030217 neurology & neurosurgeryProgressive diseaseFollow-Up StudiesMedulloblastomaInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

2014

ABSTRACT:  Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. Af…

MaleCancer Researchmedicine.medical_specialtyVatalanibDrug-Related Side Effects and Adverse ReactionsPyridinesMedizinContrast MediaAngiogenesis InhibitorsStable DiseaseText miningCarcinoma Non-Small-Cell LungmedicineHumansIn patientLung cancerAgedNeoplasm StagingClinical Trials as Topicbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRadiographyOncologyResponse Evaluation Criteria in Solid TumorsDynamic contrast-enhanced MRIDrug EvaluationPhthalazinesFemaleRadiologyNuclear medicinebusinessProgressive diseaseBiomarkersFuture oncology (London, England)
researchProduct

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

2020

Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, progressive disease on a previous treatment, and subsequent treatment with HD-SSA (either by increased administered dose [dose intensity] or…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryOctreotideNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyhigh dose80 and overMedicineProspective StudiesProspective cohort studyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogs; Adult; Aged; Aged 80 and over; Female; Follow-Up Studies; Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Prospective Studies; Retrospective Studies; Somatostatin; Cell DifferentiationAged 80 and overLiver NeoplasmsCell DifferentiationMiddle Agednonconventional dosePrognosissomatostatin analogsNeuroendocrine TumorsResponse Evaluation Criteria in Solid TumorsFemalelanreotideSomatostatinmedicine.drugAdultmedicine.medical_specialtyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogsInternal medicinenonconventional dosesHumansAdverse effectAgedRetrospective Studiesbusiness.industryBiochemistry (medical)medicine.diseaseHormonesClinical trialNETEndocrinologychemistrybusinessProgressive diseaseoctreotideFollow-Up Studies
researchProduct

Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1

2005

Progressive supranuclear palsy (PSP) is a disorder of unknown pathogenesis. Familial clusters of PSP have been reported related to mutations of protein tau. We report the linkage of a large Spanish family with typical autosomal dominant PSP to a new locus in chromosome 1. Four members of this family had typical PSP, confirmed by neuropathology in one case. At least five ancestors had similar disease. Other members of the family have incomplete phenotypes. The power of the linkage analysis was increased by detecting presymptomatic individuals with 18F-fluoro-dopa and 18F-deoxyglucose positron emission tomography. We screened the human genome with 340 polymorphic markers and we enriched the a…

MaleGenetic LinkageTau proteinLocus (genetics)NeuropathologyProgressive supranuclear palsyGenetic linkagemedicineHumansAgedBrain ChemistryGeneticsbiologyPutamenChromosomeDNAMiddle Agedmedicine.diseaseeye diseasesDihydroxyphenylalaninePedigreeChromosome 17 (human)GlucosePhenotypeNeurologyChromosomes Human Pair 1Genetic markerPositron-Emission Tomographybiology.proteinFemaleSupranuclear Palsy ProgressiveNeurology (clinical)Caudate NucleusLod ScoreRadiopharmaceuticalsAnnals of Neurology
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct

Fluency and rule breaking behaviour in the frontal cortex

2020

Design (DF) and phonemic fluency tests (FAS; D-KEFS, 2001) are commonly used to investigate voluntary generation. Despite this, several important issues remain poorly investigated. In a sizeable sample of patients with focal left or right frontal lesion we established that voluntary generation performance cannot be accounted for by fluid intelligence. For DF we found patients performed significantly worse than healthy controls (HC) only on the switch condition. However, no significant difference between left and right frontal patients was found. In contrast, left frontal patients were significantly impaired when compared with HC and right frontal patients on FAS. These lateralization findin…

MaleLIFG Left Inferior Frontal GyrusRAPM Raven's Advanced Progressive MatricesIntelligenceLMFG Left Middle Frontal GyrusLF Left frontalAudiologyCorpus callosumCVA cerebrovascular accidentATR Anterior thalamic radiationExecutive FunctionBehavioral NeurosciencePFC prefrontal cortex0302 clinical medicineVerbal fluency testHC healthy controls10. No inequalityPrefrontal cortexLanguageFASRB Phonemic Fluency Rule Breakfluid intelligenceAged 80 and overfunctionsBrain Diseasesprefrontal cortexBrain Neoplasms05 social sciencesSuperior longitudinal fasciculusGNT Graded Naming TestMiddle AgedStrokemedicine.anatomical_structurePLSM Parcel-based Lesion Symptom MappingDF Design FluencyFluid Intelligence Parcel Based Lesion Symptom Mapping tract-wise statistical analysisFemalemedicine.symptomPsychologyAdultmedicine.medical_specialtyAdolescentCognitive NeuroscienceBrain AbscessExperimental and Cognitive PsychologyGrey matterrule break errorsArticle050105 experimental psychologyLateralization of brain functionLesionWhite matterYoung Adult03 medical and health sciencesexecutivestatistical analysismedicineHumans0501 psychology and cognitive sciencesAgedParcel based lesion symptom mapping tract-wise statistical analysisSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicaphonemic and design fluencyRL Right lesionparcel based lesion symptom mapping tractwiseLL left lesionIQ Intelligence QuotientVLSM Voxel-based lesion symptom mappingrule break errorNART National Adult Reading TestPsychomotor PerformanceTSA Tract-wise Statistical Analysis030217 neurology & neurosurgeryNeuropsychologia
researchProduct

Estimation of the prevalence and incidence of motor neuron diseases in two Spanish regions: Catalonia and Valencia

2021

AbstractAccording to the degree of upper and lower motor neuron degeneration, motor neuron diseases (MND) can be categorized into amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) or progressive muscular atrophy (PMA). Although several studies have addressed the prevalence and incidence of ALS, there is a high heterogeneity in their results. Besides this, neither concept has been previously studied in PLS or PMA. Thus, the objective of this study was to estimate the prevalence and incidence of MND, (distinguishing ALS, PLS and PMA), in the Spanish regions of Catalonia and Valencia in the period 2011–2019. Two population-based Spanish cohorts were used, one from Catalonia …

MaleMalalties neuromuscularsGene ExpressionSuperoxide Dismutase-10302 clinical medicinePrevalence030212 general & internal medicineAmyotrophic lateral sclerosisEstimation theoryPrimary Lateral Sclerosismedia_commonMotor neuronsMotor Neuronseducation.field_of_studyMultidisciplinaryIncidenceIncidence (epidemiology)QRMiddle AgedProgressive muscular atrophyNeuromuscular diseasesmedicine.anatomical_structureNeurones motoresNeurologyMedicineFemaleRiskSciencemedia_common.quotation_subjectPopulationBiologyArticleMuscular Atrophy Spinal03 medical and health sciencesmedicineHumansMotor Neuron DiseaseEspanyaEstimació Teoria de l'educationAgedEstimationSelection biasMotor neurons -- DiseasesModels StatisticalC9orf72 ProteinAmyotrophic Lateral SclerosisMotor neuronmedicine.diseaseRisk factorsSpainNeurones motores -- MalaltiesMutationBiomarkers030217 neurology & neurosurgeryDemography
researchProduct

Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results

2012

PURPOSE: This study was undertaken to compare response evaluation criteria in solid tumours (RECIST) 1.1 and modified RECIST (mRECIST) in patients with unresectable hepatocellular carcinoma (HCC) on sorafenib, and to describe HCC enhancement changes before and after sorafenib treatment. METHODS AND MATERIALS: Seventeen patients (12 men, 5 women; mean age 69 years; age range 58-79 years) were included. Tumour response was assessed according to RECIST and mRECIST. Two readers placed a region of interest (ROI) within each target lesion, on the portion showing enhancement during the arterial phase. The lesion attenuation values measured within the ROIs on computed tomography or the signal inten…

MaleNiacinamideSorafenibTarget lesionmedicine.medical_specialtyCarcinoma HepatocellularContrast MediaMeglumineOrganometallic CompoundsCarcinomamedicineHumansRadiology Nuclear Medicine and imagingAgedNeuroradiologymedicine.diagnostic_testbusiness.industryPhenylurea CompoundsLiver NeoplasmsLiver CT MR HCC SorafenibMagnetic resonance imagingGeneral MedicineMiddle AgedSorafenibmedicine.diseaseMagnetic Resonance ImagingIopamidolTreatment OutcomeHepatocellular carcinomaMann–Whitney U testFemaleRadiologyTomography X-Ray ComputedbusinessProgressive diseasemedicine.drugLa radiologia medica
researchProduct